An activist investor is probing whether hedge funds are using a controversial stock-trading tactic to tip the vote in favor of pharma giant Bristol-Myers Squibb’s $74 billion deal to buy rival Celgene, The Post has learned. Starboard Value — whose boss Jeff Smith has blasted the merger as too expensive for Bristol-Myers shareholders — has...
